The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Towards a new combination therapy for tuberculosis with next generation benzothiazinones
Open accessAbstract
The benzothiazinone lead compound, BTZ043, kills Mycobacterium tuberculosis by inhibiting the essential flavo-enzyme DprE1, decaprenylphosphoryl-beta-D-ribose 2-epimerase. Here, we synthesized a new series of piperazine-containing benzothiazinones (PBTZ) and show that, like BTZ043, the preclinical candidate PBTZ169 binds covalently to DprE1. The crystal structure of the DprE1-PBTZ169 complex reveals formation of a semimercaptal adduct with Cys387 in the active site and explains the irreversible inactivation of the enzyme. Compared to BTZ043, PBTZ169 has improved potency, safety and efficacy in zebrafish and mouse models of tuberculosis (TB). When combined with other TB drugs, PBTZ169 showed additive activity against M. tuberculosis in vitro except with bedaquiline (BDQ) where synergy was observed. A new regimen comprising PBTZ169, BDQ and pyrazinamide was found to be more efficacious than the standard three drug treatment in a murine model of chronic disease. PBTZ169 is thus an attractive drug candidate to treat TB in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global tuberculosis report (2014)
Gabbasova, L. A., & Who, E. R. E. (2014) · Cited by 12,702
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 16×
“As can be seen in Fig 9, the combination of PBTZ169 and BDQ was more effective than the standard treatment in reducing the number of CFU in both organs after 1 month of treatment ( P values = 0.004 for the lung, 0.002 for the spleen) whereas the addition of PZA did not further improve the potency of the combination at…”
InfluentialSelf-citationThe challenge of new drug discovery for tuberculosis
Koul, A., Arnoult, E., Lounis, N., Guillemont, J., & Andries, K. (2011) · Nature · doi:10.1038/nature09657 · Cited by 1,042
Self-citationA small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
Advances in the development of new tuberculosis drugs and treatment regimens
Zumla, A., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 893
Self-citationThe Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Diacon, A. H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., Pistorius, C., Krause, R., Bogoshi, M., Churchyard, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808427 · Cited by 835
Self-citationMatsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., Shimokawa, Y., & Komatsu, M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030466 · Cited by 751
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
Makarov, V., Manina, G., Mikusova, K., Möllmann, U., Ryabova, O., Saint-Joanis, B., Dhar, N., Pasca, M. R., Buroni, S., Lucarelli, A. P., et al. (2009) · Science · doi:10.1126/science.1171583 · Cited by 740
Self-citationStinear, T. P., Seemann, T., Harrison, P. F., Jenkin, G. A., Davies, J. K., Johnson, P. D. R., Abdellah, Z., Arrowsmith, C., Chillingworth, T., Churcher, C., et al. (2008) · Genome Research · doi:10.1101/gr.075069.107 · Cited by 570
Self-citationDavis, J. M., Clay, H., Lewis, J. L., Ghori, N., Herbomel, P., & Ramakrishnan, L. (2002) · Immunity · doi:10.1016/s1074-7613(02)00475-2 · Cited by 565
Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-Induced Efflux Mechanism
Adams, K. N., Takaki, K., Connolly, L. E., Wiedenhoft, H., Winglee, K., Humbert, O., Edelstein, P. H., Cosma, C. L., & Ramakrishnan, L. (2011) · Cell · doi:10.1016/j.cell.2011.02.022 · Cited by 530
Tahlan, K., Wilson, R., Kastrinsky, D. B., Arora, K., Nair, V., Fischer, E., Barnes, S. W., Walker, J. R., Alland, D., Barry, C. E., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05708-11 · Cited by 504
Diacon, A. H., Dawson, R., von Groote-Bidlingmaier, F., Symons, G., Venter, A., Donald, P. R., van Niekerk, C., Everitt, D., Winter, H., Becker, P., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61080-0 · Cited by 435
Structural Basis for Benzothiazinone-Mediated Killing of Mycobacterium tuberculosis
Neres, J., Pojer, F., Molteni, E., Chiarelli, L. R., Dhar, N., Boy-Röttger, S., Buroni, S., Fullam, E., Degiacomi, G., Lucarelli, A. P., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004395 · Cited by 222
Self-citationStructural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors
Batt, S. M., Jabeen, T., Bhowruth, V., Quill, L., Lund, P. A., Eggeling, L., Alderwick, L. J., Fütterer, K., & Besra, G. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205735109 · Cited by 218
Trefzer, C., Rengifo-Gonzalez, M., Hinner, M. J., Schneider, P., Makarov, V., Cole, S. T., & Johnsson, K. (2010) · Journal of the American Chemical Society · doi:10.1021/ja106357w · Cited by 215
Self-citationLee, R. E., Protopopova, M., Crooks, E., Slayden, R. A., Terrot, M., & Barry, C. E. (2003) · Journal of Combinatorial Chemistry · doi:10.1021/cc020071p · Cited by 207
Meijer, A. H., van der Sar, A. M., da Cunha, C. B., Lamers, G. E. M., Laplante, M. A., Kikuta, H., Bitter, W., Becker, T. S., & Spaink, H. P. (2007) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2007.04.003 · Cited by 137
Self-citationLechartier, B., Hartkoorn, R. C., & Cole, S. T. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01476-12 · Cited by 126
Self-citationStoop, E. J. M., Schipper, T., Huber, S. K. R., Nezhinsky, A. E., Verbeek, F. J., Gurcha, S. S., Besra, G. S., Vandenbroucke‐Grauls, C. M. J. E., Bitter, W., & van der Sar, A. M. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.006676 · Cited by 108
Self-citationPasca, M. R., Degiacomi, G., Ribeiro, A., Zara, F., Mori, P. D., Heym, B., Mirrione, M., Brerra, R., Pagani, L., Pucillo, L. P., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01676-09 · Cited by 92
Self-citationManina, G., Bellinzoni, M., Pasca, M. R., Neres, J., Milano, A., Ribeiro, A., Buroni, S., Škovierová, H., Dianišková, P., Mikušová, K., et al. (2010) · Molecular Microbiology · doi:10.1111/j.1365-2958.2010.07277.x · Cited by 76
Self-citationSynthesis and antileprosy activity of some dialkyldithiocarbamates
Makarov, V. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl095 · Cited by 46
Self-citationMycobacteriosis: detection and identification of aquatic Mycobacterium species.
Puttinaowarat, S., Thompson, K. D., & Adams, A. (2000) · Cited by 22
Cited by
Hartkoorn, R. C., Uplekar, S., & Cole, S. T. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00037-14 · Cited by 489
Self-citationDrug Resistance Mechanisms in Mycobacterium tuberculosis
Palomino, J., & Martin, A. (2014) · Antibiotics · doi:10.3390/antibiotics3030317 · Cited by 442
Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets
Alsayed, S. S. R., & Gunosewoyo, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065202 · Cited by 332
New agents for the treatment of drug-resistant Mycobacterium tuberculosis
Hoagland, D. T., Liu, J., Lee, R. B., & Lee, R. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.026 · Cited by 328
Antibiotics in the clinical pipeline in October 2019
Butler, M. S., & Paterson, D. L. (2020) · The Journal of Antibiotics · doi:10.1038/s41429-020-0291-8 · Cited by 264
Metadata
- Authors
- Makarov, V., Lechartier, B., Zhang, M., Neres, J., van der Sar, A. M., Raadsen, S. A., Hartkoorn, R. C., Ryabova, O. B., Vocat, A., Decosterd, L. A., Widmer, N., Buclin, T., Bitter, W., Andries, K., Pojer, F., Dyson, P. J., & Cole, S. T.
- Venue
- EMBO Molecular Medicine
- Published
- 2014-02-05
- Volume
- 6
- Issue
- 3
- Pages
- 372-383
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2126989272
- Cited by
- 380
- References
- 24
- FWCI
- 20.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.